Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Implementing BiTE therapy in rural Wisconsin: A single center experience.

Thomas Oliver, Lisa Opatik Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13542

e13542 Background: Bispecific T-Cell Engagers (BiTE) are an innovative oncology treatment for patients with refractory malignancies. BiTE therapy is curre...

A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.

Zhigang Liu, Zhiqiang Wang, Zunbei Wen et al. Jun 01, 2025 pp. 6014-6014 10.1200/jco.2025.43.16_suppl.6014

6014 Background: This randomized, open-label, multicenter, blank-controlled, phase IV trial aimed to evaluate the efficacy and safety of Biyan Qingdu Gran...

Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis.

Daniel Shao-Weng Tan, Alexander E. Drilon, Jessica Jiyeong Lin et al. Jun 01, 2025 pp. 8610-8610 10.1200/jco.2025.43.16_suppl.8610

8610 Background: NTRK gene fusions are oncogenic drivers in various tumor types, including lung cancer. Larotrectinib is the first-in-class, h...

A phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies.

Jeremy L. Ramdial, Kelly Sharon Chien, Ruitao Lin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps6583

TPS6583 Background: Allogeneic hematopoietic stem cell transplantation (alloSCT) remains one of the most effective treatments for patients with myeloid ma...

Immune checkpoint inhibitors as a neoadjuvant therapy pre-liver transplantation for hepatobiliary carcinoma.

Abdullah Esmail, Maen Abdelrahim Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14624

e14624 Background: Hepatobiliary carcinoma (HBC) is the sixth most prevalent cancer worldwide, with hepatocellular carcinoma (HCC) being the most common p...

Association of lifestyle factors and pathological characteristics in patients with early breast cancer and overweight/obesity: Results from the Breast Cancer Weight Loss (BWEL) trial.

Caterina Sposetti, Karla V. Ballman, Linda Mackie McCall et al. Jun 01, 2025 pp. 561-561 10.1200/jco.2025.43.16_suppl.561

561 Background: Obesity and other lifestyle factors are associated with breast cancer (BC) risk and outcomes. These relationships appear to vary in pre- v...

Assessment of Onco+, a personalized navigation support, for oncology clinical trials in Quebec.

Catherine Vayssier, Lucie D'Amours, Marco Décelles et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23114

e23114 Background: Quebec-Clinical Research Organization in Cancer (Q-CROC), a not-for-profit organization, has the mission to improve accessibility to on...

Assessment of weight change and BMI as prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in a Polish female cohort.

Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, Manuela Las-Jankowska et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13144

e13144 Background: Body mass index (BMI) and weight changes are often studied as prognostic markers in breast cancer (BC). While higher BMI is associated...

Efficacy outcomes of CDK4/6 inhibitors plus endocrine therapy versus chemotherapy in HR+/HER2- breast cancer: A systematic review and meta-analysis.

Raelson Rodrigues Miranda, Gabrielle Trofa, Luisa Canesin Costa et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13065

e13065 Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) represent the standard of care for advanced o...

AI-driven integration of microbiome and exosome profiles for precision diagnostics and therapeutics in colorectal cancer.

Emile Youssef, Daniel Kowalski, Brandon Ocia Fletcher et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13634

e13634 Background: Exosomes and the microbiome are emerging as critical components in precision oncology, offering innovat...

Demographic, geographic, and facility-specific trends in malignant neoplasms of the bile duct mortality in the United States (1999–2020).

Aqsa Zoey Sorathia, Hasan Munshi, Islam Rajab et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22590

e22590 Background: Malignant neoplasms of the bile duct are rare but highly fatal cancers. Identifying mortality trends across race, gender, geography, an...

The preoperative management of patients with giant cell tumors in limb bones using denosumab therapy.

Saidrasul Nasirov, Djamila Polatova, Khurshid Abdikarimov et al. Jun 01, 2025 pp. 11520-11520 10.1200/jco.2025.43.16_suppl.11520

11520 Background: Giant cell tumor (GCT) is an intermediate, locally aggressive primary bone tumor. In addition to local therapy,new drugs for the treatme...

Prospective validation of the Cancer and Aging Research Group fall-risk score for older adults with cancer.

Tanya Marya Wildes, Kevin Kupzuk, Laura LaNiel Tenner et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23195

e23195 Background: In older adults with cancer, falls are associated with poorer quality of life, chemotherapy toxicity & shorter survival, yet fall r...

Identifying barriers to implementing survivorship support programs for oncology patients.

Smriti Nair, Trishya Srinivasan, Deidre Geroni et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13872

e13872 Background: Disparities in cancer survivorship can influence the quality of life and access to resources. Understanding and addressing these dispar...

The utility of one-step nucleic acid amplification in detecting sentinel lymph node metastases in colorectal cancer: A systematic review and meta-analysis.

Mohamed E. Ali, Ahmed Msherghi, Mohammed S. Beshr et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15581

e15581 Background: Sentinel lymph node (SLN) assessment is critical in colorectal cancer (CRC) for accurate staging and determining optimal treatment stra...

Genomic landscape and precision therapeutics in follicular thyroid cancer: Insights from the AACR Project GENIE.

Beau Hsia, Julia Kuzniar, Joey Luzarraga et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18142

e18142 Background: Follicular thyroid carcinoma (FTC), the second most common thyroid cancer, is diagnostically challenging due to overlapping features wi...

Safety and efficacy of anti-CEA CAR-T cells to prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection.

Wei Zhang, Leqi Zhou, Guanyu Yu et al. Jun 01, 2025 pp. 3541-3541 10.1200/jco.2025.43.16_suppl.3541

3541 Background: Approximately 75% of colorectal cancer liver metastasis patients relapse within two years after surgery due to circulating tumor cells an...

The efficacy of diagnostic imaging for superficial soft tissue masses on a community level.

Colton Cox, Kyren Maynard, Leila Hollis et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23547

e23547 Background: Ultrasound and magnetic resonance imaging (MRI) have both demonstrated high sensitivity and specificity in the diagnosis of soft tissue...

Clinicopathologic determinants of survival of hepatoid adenocarcinoma of the lungs: Analysis of a pooled database.

Philip A. Haddad, Vishal Devarkonda, Kavitha Beedupalli et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20045

e20045 Background: Hepatoid adenocarcinoma of the lung (HAL) is a rare and aggressive subtype of thoracic cancer characterized by morphological similariti...

Outcomes of older matched sibling donors compared to younger matched unrelated donors in allogeneic hematopoietic cell transplantation for AML in first complete remission.

Jiasheng Wang, Gabriela Sanchez-Petitto, Hannah Kyung Choe et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18558

e18558 Background: Matched sibling donors (MSDs) have long been the preferred choice for allogeneic HCT. However, recent studies suggest younger donors ma...

Outcomes after stem cell boost for poor engraftment following allogeneic hematopoietic stem cell transplantation for patients with primary and secondary myelofibrosis.

Maria Leon-Camarena, Leah Philips, Colin Anthony Vale et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18561

e18561 Background: The introduction of JAK2 inhibitors has improved symptom control for patients with myelofibrosis (MF), but allogeneic hematopoietic ste...

Exploring variables associated with prolonged survival in AML with TP53 aberration.

Patrick Willard, Thuy Ho, Sarah Grace Durisek et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18519

e18519 Background: Acute myeloid leukemia (AML) with TP53 aberration is associated with poor survival and therapeutic refractoriness, with median overall...

Real-world antibody-drug conjugate (ADC) sequential use in metastatic breast cancer.

Jiayi Tan, David Lin, Yeonjoo Choi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13122

e13122 Background: The advent of antibody-drug conjugates (ADCs) has significantly expanded the therapeutic landscape for metastatic breast cancer (MBC)....

The top 10 Italian priorities in renal cell carcinoma (RCC): A people-centered approach to cancer care for future research.

Sarah Scagliarini, Brigida Maiorano, Giovanna Pecoraro et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16522

e16522 Background: The management of RCC has advanced considerably in recent years, highlighting the need for research priorities to integrate clinicians...

Qingre huoxue formula and its key active components as associated with multi-targeted effects on human pancreatic cancer cells.

Fuchun Si, Haiyang Du, Gao Si et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16446

e16446 Background: Pancreatic cancer (PC) exhibits a high mortality rate, often diagnosed at advanced stages with limited therapeutic options. Traditional...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page